FindTrial
Sign In

REAL WORLD OUTCOMES OF OSIMERTINIB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH POSITIVE EGFR T790M MUTATION : A MULTICENTER RETROSPECTIVE COHORT STUDY IN SOUTH KOREA

REAL WORLD OUTCOMES OF OSIMERTINIB FOR NON-SMALL CELL LUNG CANCER PATIENTS WITH POSITIVE EGFR T790M MUTATION : A MULTICENTER RETROSPECTIVE COHORT STUDY IN SOUTH KOREA

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0006341
Enrollment
500
Registered
2021-07-13
Start date
2021-10-07
Completion date
Unknown
Last updated
2026-01-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Asan Medical Center
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: 1) Male or female subjects 20 years of age or older at the time of diagnosis 2) Patients with histologically or cytologically proven diagnosis of EGFR T790M positive NSCLC 3) Patients who were treated with Osimertinib between Jan 1st, 2018 and June 30th, 2020

Exclusion criteria

Exclusion criteria: 1) Patients who received osimertinib in clinical trial setting 2) Patients whose medical records are not available for review

Design outcomes

Primary

MeasureTime frame
Progression-free survival (PFS)—

Secondary

MeasureTime frame
Treatment profiles of Osimertinib; Duration of response (DoR); Disease control rate (DCR) at 6 and 12 weeks;Time to overall progression [TTP], time to intracranial progression [IC-TTP], time to extracranial progression [EC-TTP];Overall survival (OS)—

Countries

Korea, Republic of

Contacts

Public ContactJae Cheol Lee

Asan Medical Center

jclee@amc.seoul.kr+82-2-3010-3208

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026